Nurix Therapeutics (NRIX) Analysis Clinical Milestone:
Nurix Therapeutics NASDAQ:NRIX , a clinical-stage biotech company, achieved a significant milestone with its NX-5948 leukemia drug, showing a 69.2% positive response in a trial for relapsed or refractory chronic lymphocytic leukemia (CLL). Needham analyst Gil Blum praised these results as a "clear win."
Strategic Collaborations:
Nurix is also advancing collaborations with major pharma companies. It is set to nominate a development candidate with Sanofi this year, positioning it for substantial breakthroughs. Additionally, Gilead Sciences extended its research collaboration with Nurix by two years, highlighting Nurix's robust R&D capabilities.
Investment Outlook:
Bullish Outlook: We are bullish on NRIX above the $15.00-$16.00 range.
Upside Potential: With a target set at $30.00-$31.00, investors should consider Nurix's promising clinical results and strategic partnerships as key drivers for potential stock growth.
๐๐งฌ Monitor Nurix Therapeutics for promising investment opportunities! #NRIX #Biotech ๐๐
NRIX trade ideas
Nurix TherapeuticsNurix Therapeutics witnessed a strong rebound in yesterday's session, violating the last peak at 18.12, and remaining above this level in today's session, will confirm this breakout, which will confirm the current uptrend, with higher targets near 19.92 - 21.53 - 24 - 25.46 - 27.30.
The stop-loss lies below 17.28.
the indicators are heading toward the positive side, which confirms the mentioned positive scenario.
The information and publications are not intended to be or constitute any financial, investment, commercial, or other types of advice or recommendations provided.